Publicaciones en colaboración con investigadores/as de Pfizer (United States) (21)

2023

  1. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

2022

  1. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293

  2. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

    npj Precision Oncology, Vol. 6, Núm. 1

  3. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390

  4. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530

  3. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

2020

  1. Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 1, pp. 110-121

  2. Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

    JNCI Cancer Spectrum, Vol. 4, Núm. 1

  3. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

    Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180

  4. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535

2018

  1. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

    Annals of Oncology, Vol. 29, Núm. 3, pp. 669-680

  2. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: Results from the PALOMA-2 trial

    Annals of Oncology, Vol. 29, Núm. 4, pp. 888-894

  3. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial

    Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947

  4. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

    New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763

2016

  1. Palbociclib and letrozole in advanced breast cancer

    New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936

2013

  1. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3763-3772

2012

  1. Incidence-based cost-of-illness model for metastatic breast cancer in the United States

    International Journal of Technology Assessment in Health Care, Vol. 28, Núm. 1, pp. 12-21